Mark Connor


  • 4604 Citations
  • 39 h-Index
1991 …2019
If you made any changes in Pure these will be visible here soon.

Personal profile


I am Pharmacologist interested in analgesics and other psychoactive drugs, particularly cannabinoids and opioids. My lab studies how opioids, cannabinoids and related molecules interact with G protein coupled receptors and ion channels to exert their effects. Currently my work is focussed on how clinically used opioids interact with naturally occuring variants of human opioid receptors, the pharmacology and toxicity of emerging synthetic cannabinoid receptors agonists (Spice/K2) and the molecular mechanisms underlying the potential therapeutic actions of cannabis and its components.

Education/Academic qualification

Pharmacology, PhD, University of Washington

Pharmacology, Genetics, BSc (Hons), University of Sydney

Fingerprint Fingerprint is based on mining the text of the person's scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 3 Similar Profiles
mu Opioid Receptor Medicine & Life Sciences
Opioid Analgesics Medicine & Life Sciences
Cannabinoids Medicine & Life Sciences
Pharmacology Medicine & Life Sciences
Neurons Medicine & Life Sciences
Periaqueductal Gray Medicine & Life Sciences
Ligands Medicine & Life Sciences
Calcium Channels Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2008 2019

Research Output 1991 2019

New-generation azaindole-adamantyl-derived synthetic cannabinoids

Longworth, M., Reekie, T. A., Blakey, K., Boyd, R., Connor, M. & Kassiou, M., 28 Feb 2019, In : Forensic Toxicology.

Research output: Contribution to journalArticleResearchpeer-review

Mass spectrometry
Mass Spectrometry

Regulation of heterologously expressed 5-HT1B receptors coupling to potassium channels in AtT-20 cells

Heblinski, M., Bladen, C. & Connor, M., 1 Feb 2019, In : British Journal of Pharmacology. 176, 3, p. 451-465 15 p.

Research output: Contribution to journalArticleResearchpeer-review

Receptor, Serotonin, 5-HT1B
Potassium Channels
G Protein-Coupled Inwardly-Rectifying Potassium Channels

Synthesis and pharmacology of new psychoactive substance 5F-CUMYL-P7AICA, a scaffold- hopping analog of synthetic cannabinoid receptor agonists 5F-CUMYL-PICA and 5F-CUMYL-PINACA

Banister, S. D., Adams, A., Kevin, R. C., Macdonald, C., Glass, M., Boyd, R., Connor, M., McGregor, I. S., Havel, C. M., Bright, S. J., Vilamala, M. V., Lladanosa, C. G., Barratt, M. J. & Gerona, R. R., Feb 2019, In : Drug Testing and Analysis. 11, 2, p. 279-291 13 p.

Research output: Contribution to journalArticleResearchpeer-review

Artificial Receptors
Cannabinoid Receptor Agonists
nuclear magnetic resonance
liquid chromatography

Conformationally rigid derivatives of WAY-267,464: synthesis and pharmacology at the human oxytocin and vasopressin-1a receptors

Jorgensen, W. T., Gulliver, D. W., Katte, T. A., Werry, E. L., Reekie, T. A., Connor, M. & Kassiou, M., 1 Jan 2018, In : European Journal of Medicinal Chemistry. 143, p. 1644-1656 13 p.

Research output: Contribution to journalArticleResearchpeer-review

Oxytocin Receptors
Vasopressin Receptors

The chemistry and pharmacology of synthetic cannabinoid receptor agonists as new psychoactive substances: origins

Banister, S. & Connor, M., 1 Jan 2018, New psychoactive substances: pharmacology, clinical, forensic and analytical toxicology. Maurer, H. H. & Brandt, S. D. (eds.). Switzerland, p. 165-190 26 p. (Handbook of Experimental Pharmacology; vol. 252).

Research output: Chapter in Book/Report/Conference proceedingChapterResearchpeer-review

Artificial Receptors
Cannabinoid Receptor Agonists
Cannabinoid Receptor CB1
Cannabinoid Receptor CB2